NantHealth (NH) Receives Consensus Recommendation of “Buy” from Analysts

NantHealth (NASDAQ:NH) has been given a consensus rating of “Buy” by the six research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $4.69.

A number of equities analysts have recently issued reports on the stock. BidaskClub upgraded shares of NantHealth from a “hold” rating to a “buy” rating in a research report on Wednesday, May 9th. ValuEngine upgraded shares of NantHealth from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Cowen restated a “buy” rating and set a $4.50 target price on shares of NantHealth in a research report on Tuesday, March 20th. Finally, Jefferies Group set a $5.00 target price on shares of NantHealth and gave the stock a “buy” rating in a research report on Wednesday, March 21st.

Get NantHealth alerts:

In related news, COO Ronald Allen Louks sold 7,095 shares of NantHealth stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $3.56, for a total value of $25,258.20. Following the transaction, the chief operating officer now directly owns 89,690 shares in the company, valued at approximately $319,296.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last quarter, insiders sold 21,105 shares of company stock worth $70,440. 58.00% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of NH. Citadel Advisors LLC acquired a new stake in NantHealth in the fourth quarter valued at $103,000. Schwab Charles Investment Management Inc. acquired a new stake in NantHealth in the third quarter valued at $180,000. Deutsche Bank AG lifted its holdings in NantHealth by 117.4% in the fourth quarter. Deutsche Bank AG now owns 45,610 shares of the company’s stock valued at $137,000 after acquiring an additional 24,635 shares during the period. SG Americas Securities LLC lifted its holdings in NantHealth by 157.6% in the fourth quarter. SG Americas Securities LLC now owns 72,521 shares of the company’s stock valued at $221,000 after acquiring an additional 44,372 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in NantHealth in the third quarter valued at $365,000. Hedge funds and other institutional investors own 5.59% of the company’s stock.

Shares of NantHealth stock opened at $3.48 on Friday. The company has a market capitalization of $363.78 million, a price-to-earnings ratio of -3.11 and a beta of 0.19. NantHealth has a 52 week low of $2.60 and a 52 week high of $5.26. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.88 and a current ratio of 1.90.

NantHealth (NASDAQ:NH) last announced its earnings results on Wednesday, March 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $22.30 million for the quarter, compared to analysts’ expectations of $23.50 million. NantHealth had a negative return on equity of 63.06% and a negative net margin of 168.84%. analysts anticipate that NantHealth will post -0.61 EPS for the current fiscal year.

NantHealth Company Profile

NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.